Ocrevus subcutaneous maintains consistent benefit-risk profile after two years

Ocrevus皮下注射在两年后保持一致的效益-风险特征

New late-breaking data confirms Ocrevus significantly reduces disability progression in adults with advanced PPMS

新近发布的数据证实，Ocrevus 显著减少了进展型多发性硬化症（PPMS）成人患者的残疾进展。

One-year data reinforce that majority of infants potentially exposed to Ocrevus during pregnancy or breastfeeding exhibit antibody responses

一年的数据证实，大多数在怀孕或哺乳期间可能接触过奥克雷珠单抗的婴儿表现出抗体反应。

Fenebrutinib two-year Phase II data demonstrate near-complete suppression of disease activity at 96 weeks

两年期的Fenebrutinib II期数据显示，在96周时疾病活动几乎完全被抑制。

South San Francisco, CA -- September 23, 2025 --

加利福尼亚州南旧金山 -- 2025年9月23日 --

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus

基因泰克，罗氏集团（SIX: RO, ROG; OTCQX: RHHBY）的成员，公布了Ocrevus的新数据。

®

®

(ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (September 24-26 ).

在西班牙巴塞罗那举行的第41届欧洲多发性硬化症治疗和研究委员会（ECTRIMS）大会（9月24日至26日）上，展示了ocrelizumab和实验性的布鲁顿酪氨酸激酶（BTK）抑制剂fenebrutinib。

New data show that treatment with Ocrevus provides significant benefit in preventing disability progression across diverse groups of people with multiple sclerosis (MS), including children with relapsing-remitting multiple sclerosis (RRMS), women with MS who are pregnant or breastfeeding, and adults with advanced primary progressive multiple sclerosis (PPMS).

新数据显示，使用奥克瑞珠单抗（Ocrevus）治疗在预防多发性硬化症（MS）不同人群的残疾进展方面具有显著益处，包括复发缓解型多发性硬化症（RRMS）的儿童、怀孕或哺乳期的女性多发性硬化症患者，以及患有晚期原发性进展型多发性硬化症（PPMS）的成人。

From Genentech’s MS pipeline, Phase II data for fenebrutinib showing near-complete suppression of disease activity at 96 weeks will be presented ahead of upcoming pivotal study readouts. .

来自基因泰克的多发性硬化症管线，将在即将到来的关键研究结果公布之前，展示芬尼布替尼在第96周时近乎完全抑制疾病活动的二期数据。

'We have made significant scientific progress in the treatment of MS and improving outcomes for people living with it, including key life moments such as planning for a family,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “With over a decade of efficacy and safety evidence, Ocrevus has transformed the course of MS for people with RMS and PPMS, and the new data further reinforce its role in preventing disability progression.

“我们在多发性硬化症（MS）的治疗上取得了显著的科学进展，并改善了患者的生活质量，包括规划家庭等关键人生时刻，”基因泰克首席医学官兼全球产品开发主管Levi Garraway博士表示。“凭借十多年来的疗效和安全性证据，Ocrevus已经改变了复发缓解型多发性硬化症（RMS）和原发进展型多发性硬化症（PPMS）患者的病程，而新数据进一步巩固了其在预防残疾进展中的作用。”

We are also encouraged by the potential of fenebrutinib in redefining future treatment.” .

我们对fenebrutinib在重新定义未来治疗方面的潜力也感到鼓舞。”

“ECTRIMS 2025 marks over a decade of scientific advancement since the first Phase III pivotal data from Ocrevus. The deepened understanding of B cells has led to breakthrough therapies that have revolutionized MS management by focusing on slowing disease progression,” said Professor Stephen L. Hauser, Director of the UCSF Weill Institute for Neurosciences.

“自Ocrevus首次发布III期关键数据以来，ECTRIMS 2025标志着科学进步已超过十年。对B细胞的深入理解带来了突破性的疗法，通过专注于减缓疾病进展，彻底改变了多发性硬化症（MS）的管理方式，”加州大学旧金山分校威尔神经科学研究所主任Stephen L. Hauser教授表示。

“While significant progress has been made, continued innovation focused on preventing both relapses and progression is essential to empowering people with MS to live life to the fullest. This year’s breadth of data demonstrates our collective commitment towards achieving these goals.”.

“虽然已经取得了显著的进展，但为了使多发性硬化症患者能够充分享受生活，继续专注于预防复发和疾病进展的创新仍然至关重要。今年的广泛数据展示了我们为实现这些目标所做出的共同努力。”

Two-year Ocrevus subcutaneous Phase III data

两年期Ocrevus皮下注射三期数据

Final data from the Phase III OCARINA II study show that Ocrevus subcutaneous (SC) injection maintains a consistent benefit-risk profile for up to two years, similar to the well-established Ocrevus intravenous infusion (IV), with continued near-complete suppression of relapses, brain lesion activity and disability progression. .

OCARINA II 三期研究的最终数据显示，长达两年的时间内，Ocrevus 皮下注射（SC）保持了与已确立的 Ocrevus 静脉输注（IV）一致的效益风险特征，持续近乎完全抑制复发、脑部病灶活动和残疾进展。

Phase IIIb Ocrevus results in broad PPMS population

第三阶段b期Ocrevus在广泛的PPMS人群中取得结果

The ORATORIO-HAND expanded on the PPMS population studied in the registrational ORATORIO study by including older patients (age up to 65) and patients with advanced disability (Expanded Disability Status Scale [EDSS] score up to 8.0), for whom maintaining upper limb function is even more important for preserving quality of life and independence. .

ORATORIO-HAND 在注册性 ORATORIO 研究的基础上扩展了对 PPMS 人群的研究，纳入了年龄较大（最高至 65 岁）以及残疾程度较重（扩展残疾状态量表 [EDSS] 评分最高至 8.0）的患者，对于这些患者而言，维持上肢功能对保持生活质量和独立性尤为重要。

Ocrevus shows 30% reduction in the risk of time to onset of 12-week composite confirmed disability progression (cCDP) in adults with advanced PPMS compared to placebo after a median 2.75 years of treatment (p=0.0007) in new late-breaking data from the Phase IIIb ORATORIO-HAND study. An even greater reduction of 55% in the risk of time to onset of 12-week cCDP was observed in patients with MRI lesion activity at baseline (p<0.0001). .

在第三阶段b ORATORIO-HAND研究的新晚期数据中，与安慰剂相比，Ocrevus在治疗中位时间为2.75年后，将进展型多发性硬化症（PPMS）成人患者12周复合确认残疾进展（cCDP）的发病时间风险降低了30%（p=0.0007）。而在基线时有MRI病灶活动的患者中，12周cCDP发病时间的风险更是显著降低了55%（p<0.0001）。

In a large PPMS population that included patients with more advanced disease, Ocrevus was superior to placebo in delaying overall disability progression (EDSS) and worsening of upper limb function (9-hole peg test).

在包括病情较重患者的大规模PPMS人群中，Ocrevus在延缓总体残疾进展（EDSS）和上肢功能恶化（9孔插板测试）方面优于安慰剂。

The safety profile of Ocrevus was consistent with previous studies, and no new safety signals were reported. Ocrevus is the first and only approved treatment for PPMS, and these data demonstrate that the benefit extends to patients with more advanced disease.

Ocrevus 的安全性与之前的研究一致，没有报告新的安全问题。Ocrevus 是首个也是唯一获批用于治疗 PPMS 的药物，这些数据表明其益处可以延展到病情更严重的患者身上。

Infant outcomes in pregnant and breastfeeding women treated with Ocrevus

接受Ocrevus治疗的孕妇和哺乳期妇女的婴儿结局

An analysis of more than 5,000 pregnancies from the ocrelizumab pregnancy registry, the largest dataset of pregnancy outcomes for an anti-CD20 therapy in MS, will reinforce previous data that showed in-utero exposure to Ocrevus does not increase the risk of adverse pregnancy or infant outcomes.

对来自奥瑞珠单抗妊娠登记处的超过5000例妊娠进行分析，这是有关多发性硬化症抗CD20治疗中妊娠结果的最大数据集，该分析将进一步巩固之前的数据，即子宫内暴露于奥瑞珠单抗不会增加不良妊娠或婴儿结局的风险。

The majority of infants with potential Ocrevus exposure during pregnancy or breastfeeding exhibited meaningful antibody responses to childhood vaccines in one-year data from the Phase IV MINORE and SOPRANINO studies. Protective antibody responses to eight common vaccines given in the first year of life were observed in 86-100% of infants with potential exposure to Ocrevus during their mother’s pregnancy in MINORE and in 78-100% of infants with potential exposure to Ocrevus during breastfeeding in SOPRANINO.

在第四阶段MINORE和SOPRANINO研究的一年数据中，大多数在怀孕或哺乳期间可能接触Ocrevus的婴儿对儿童疫苗表现出有意义的抗体反应。在MINORE研究中，母亲怀孕期间可能接触Ocrevus的婴儿中有86-100%对出生后第一年内接种的八种常见疫苗产生了保护性抗体反应；而在SOPRANINO研究中，哺乳期间可能接触Ocrevus的婴儿中有78-100%产生了类似的抗体反应。

This means these children can recognize and fight the disease if encountered later, preventing severe illness and long-term harm. .

这意味着，这些孩子如果以后再接触到这种疾病，就能够识别并抵抗它，从而防止重症和长期伤害。

Infant B-cell levels also remained within normal range after 13 months in 95% (n=20/21) of infants in MINORE and 100% (n=11/11) of infants in SOPRANINO. Further data on the growth and development of infants with potential Ocrevus exposure during the first year of life will also be presented.

在MINORE研究中，95%（n=20/21）的婴儿和在SOPRANINO研究中100%（n=11/11）的婴儿在13个月后B细胞水平仍然保持在正常范围内。关于在生命第一年可能暴露于Ocrevus的婴儿生长发育的更多数据也将被展示。

Ocrevus in pediatric RRMS

奥克瑞珠单抗在儿童复发缓解型多发性硬化症中的应用

Late-breaking data from the Phase III OPERETTA 2 study investigating efficacy and safety of Ocrevus in children 10–17 years of age with RRMS will be presented on September 26 at 10:30 CEST. The OPERETTA 2 presentation will be the first time that data from the primary analysis of a pediatric-onset MS trial comparing a high-efficacy DMT (ocrelizumab) versus a globally approved treatment (fingolimod) will be shown.

第三期 OPERETTA 2 研究的最新数据将于 9 月 26 日欧洲中部时间 10:30 发表，该研究评估了 Ocrevus 在 10 至 17 岁复发-缓解型多发性硬化症（RRMS）儿童中的疗效与安全性。OPERETTA 2 的报告将是首次展示来自针对早发性多发性硬化症试验的主要分析数据，该试验比较了一种高效疾病修饰治疗药物（奥克瑞珠单抗）与一种全球获批的疗法（芬戈莫德）的效果。

Also, long-term, 96-week results from the Phase II OPERETTA 1 pediatric study will be an oral presentation on September 25 at 15:15 CEST. .

此外，来自二期OPERETTA 1儿科研究的长期96周结果将于9月25日15:15（中欧夏令时间）进行口头报告。

Fenebrutinib two-year Phase II FENopta OLE results

Fenebrutinib两年二期FENopta OLE结果

Two-year data from the Phase II FENopta open-label extension (OLE) study will be presented, showing that patients with relapsing multiple sclerosis (RMS) treated with fenebrutinib maintained near-complete suppression of disease activity at 96 weeks. Patients enrolled in the OLE had a low annualized relapse rate (ARR) of 0.06, and during this time, there was no disability progression, as measured by the EDSS.

将展示二期FENopta开放标签扩展（OLE）研究的两年数据，结果显示，接受fenebrutinib治疗的复发缓解型多发性硬化症（RMS）患者在96周时疾病活动几乎完全被抑制。参与OLE研究的患者的年复发率（ARR）为0.06，在此期间，通过EDSS测量，未出现残疾进展。

At two years, MRI scans detected zero new T1 gadolinium-enhancing (T1-Gd+) lesions, which are markers of active inflammation..

两年时，MRI扫描未发现新的T1钆增强（T1-Gd+）病灶，这些病灶是活动性炎症的标志。

Neurofilament light chain, a marker of nerve cell damage, was decreased to healthy donor range in the first year and maintained in the second year of fenebrutinb treatment. Three Phase III clinical trials for fenebrutinib are ongoing, including the FENhance I and II studies in RMS and the FENtrepid study in PPMS.

神经丝轻链是神经细胞损伤的标志物，在使用fenebrutinib治疗的第一年降至健康捐赠者范围内，并在第二年得以维持。三项关于fenebrutinib的III期临床试验正在进行中，其中包括FENhance I和II研究（针对RMS）以及FENtrepid研究（针对PPMS）。

Initial data from the FENtrepid study are expected at the end of this year. .

预计今年年底将获得FENtrepid研究的初步数据。

In total, Genentech and Roche will present 25 abstracts, including six oral and four late-breaking presentations at ECTRIMS 2025. Follow Genentech on X via @Genentech and keep up to date with ECTRIMS 2025 news and updates by using the hashtag #ECTRIMS2025.

总计，基因泰克和罗氏将在2025年ECTRIMS大会上展示25篇摘要，其中包括六场口头报告和四场最新突破性报告。关注基因泰克的X账号@Genentech，并通过标签#ECTRIMS2025获取2025年ECTRIMS的最新消息和更新。

About Ocrevus

关于Ocrevus

®

®

(ocrelizumab)

(奥克雷珠单抗)

Ocrevus is a humanized monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. Ocrevus IV and Ocrevus subcutaneous (SC; marketed as Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq] in the U.S.) are the only therapies approved for both RMS (including relapsing-remitting multiple sclerosis [RRMS] and active, secondary progressive multiple sclerosis [SPMS], as well as clinically isolated syndrome [CIS] in the U.S.) and primary progressive multiple sclerosis (PPMS).

Ocrevus是一种人源化单克隆抗体，旨在靶向CD20阳性B细胞，这是一种特定类型的免疫细胞，被认为是对髓鞘（神经细胞的绝缘和支持）和轴突（神经细胞）损伤的主要贡献者。Ocrevus静脉注射和Ocrevus皮下注射（SC；在美国市场以Ocrevus Zunovo® [ocrelizumab hyaluronidase-ocsq]销售）是唯一被批准用于治疗RMS（包括复发缓解型多发性硬化症[RRMS]、活动性继发进展型多发性硬化症[SPMS]，以及在美国的临床孤立综合征[CIS]）和原发进展型多发性硬化症（PPMS）的疗法。

Both Ocrevus IV and SC are administered every six months. The initial IV dose is given as two 300 mg infusions two weeks apart with subsequent doses given as single 600 mg infusions. Ocrevus SC is given as a single 920 mg subcutaneous injection every six months..

Ocrevus 静脉注射和皮下注射均每六个月给药一次。初始静脉注射剂量分为两次300毫克输注，间隔两周，随后的剂量为单次600毫克输注。Ocrevus 皮下注射则每六个月进行一次单次920毫克的皮下注射。

About fenebrutinib

关于fenebrutinib

Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimized pharmacokinetics (PK) profile. Fenebrutinib has been shown to be 130 times more selective for BTK vs. other kinases. Fenebrutinib is an inhibitor of both B-cell and microglia activation.

Fenebrutinib 是一种研究性口服、可穿透中枢神经系统 (CNS)、可逆且非共价的布鲁顿酪氨酸激酶 (BTK) 抑制剂，具有优化的药代动力学 (PK) 特性。研究表明，Fenebrutinib 对 BTK 的选择性比其他激酶高 130 倍。Fenebrutinib 能够抑制 B 细胞和小胶质细胞的活化。

This dual inhibition may be able to reduce both multiple sclerosis disease activity and disability progression, thereby potentially addressing the key unmet medical need of disability progression in people living with multiple sclerosis and providing comprehensive MS care. The fenebrutinib Phase III program includes two identical trials in relapsing multiple sclerosis (RMS) (FENhance 1 & 2) with active comparator teriflunomide and the only trial in primary progressive multiple sclerosis (PPMS) (FENtrepid) in which a BTK inhibitor is being evaluated against Ocrevus. .

这种双重抑制可能能够减少多发性硬化症的疾病活动性和残疾进展，从而潜在地解决多发性硬化症患者未满足的关键医疗需求，即残疾进展，并提供全面的多发性硬化症护理。Fenebrutinib 的 III 期项目包括两项相同的复发缓解型多发性硬化症 (RMS) 试验（FENhance 1 和 2），以特立氟胺为活性对照，以及唯一一项在原发进展型多发性硬化症 (PPMS) 中的试验（FENtrepid），在该试验中，一种 BTK 抑制剂正在与奥瑞珠单抗进行比较。

About multiple sclerosis

关于多发性硬化症

Multiple sclerosis (MS) is a chronic disease that affects more than 2.9 million people worldwide. MS occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the central nervous system (brain, spinal cord and optic nerves), causing inflammation and consequent damage.

多发性硬化症 (MS) 是一种慢性疾病，影响全球超过 290 万人。当免疫系统异常攻击中枢神经系统（大脑、脊髓和视神经）中神经细胞的绝缘层和支持结构（髓鞘）时，就会发生多发性硬化症，导致炎症并造成相应的损害。

This damage can cause a wide range of symptoms, including weakness, fatigue and difficulty seeing, and may eventually lead to disability. Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of acquired non-traumatic disability in younger adults..

这种损害可能导致各种各样的症状，包括虚弱、疲劳和视力困难，并最终可能导致残疾。大多数多发性硬化症患者在20至40岁之间首次出现症状，这使得该疾病成为年轻成年人中导致后天非创伤性残疾的主要原因。

People with all forms of MS experience disease progression – permanent loss of nerve cells in the central nervous system – from the beginning of their disease even if their symptoms aren’t apparent or don’t appear to be getting worse. Delays in diagnosis and treatment can negatively impact people with MS, in terms of their physical and mental health, and contribute to the negative financial impact on the individual and society.

所有形式的多发性硬化症患者从发病初期就会经历疾病进展——即使症状不明显或似乎没有恶化，其中枢神经系统也会永久丧失神经细胞。诊断和治疗的延误会对多发性硬化症患者的身心健康产生负面影响，并对个人和社会造成负面的经济影响。

An important goal of treating MS is to slow, stop and ideally prevent progression as early as possible..

治疗多发性硬化症的一个重要目标是尽可能早地减缓、阻止并理想地防止病情进展。

Relapsing-remitting MS (RRMS) is the most common form of the disease and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. Approximately 85% of people with MS are initially diagnosed with RRMS. The majority of people who are diagnosed with RRMS will eventually transition to secondary progressive MS (SPMS), in which they experience steadily worsening disability over time.

复发缓解型多发性硬化症（RRMS）是最常见的疾病形式，其特征是出现新的或恶化的症状（复发）的发作，随后是恢复期。大约85%的多发性硬化症患者最初被诊断为RRMS。大多数被诊断为RRMS的人最终会发展为继发进展型多发性硬化症（SPMS），他们的残疾程度会随着时间的推移而持续加重。

Relapsing forms of MS (RMS) include people with RRMS and people with SPMS who continue to experience relapses. Primary progressive MS (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with MS are diagnosed with the primary progressive form of the disease.

多发性硬化症的复发形式（RMS）包括患有复发缓解型多发性硬化症（RRMS）的人，以及继续经历复发的继发进展型多发性硬化症（SPMS）患者。原发进展型多发性硬化症（PPMS）是一种致残性的疾病形式，其特征是症状逐渐恶化，但通常没有明显的复发或缓解期。大约15%的多发性硬化症患者被诊断为原发进展型。

Until the FDA approval of Ocrevus intravenous (IV) infusion, there had been no FDA-approved treatments for PPMS and Ocrevus IV and Ocrevus Zunovo are the only approved treatments for PPMS..

在FDA批准Ocrevus静脉（IV）输注之前，尚无FDA批准的针对PPMS的治疗方法，而Ocrevus IV和Ocrevus Zunovo是唯一获批用于PPMS的治疗药物。

About Genentech in neuroscience

关于基因泰克在神经科学领域

Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

神经科学是基因泰克和罗氏研究与开发的主要焦点。我们的目标是追求开创性的科学，开发新的治疗方法，帮助改善慢性病和潜在破坏性疾病患者的生活。

Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, stroke, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today..

基因泰克和罗氏正在研究十多种针对神经疾病的药物，包括多发性硬化症、中风、阿尔茨海默病、亨廷顿病、帕金森病、杜氏肌营养不良症和自闭症谱系障碍。与我们的合作伙伴一起，我们致力于突破科学认知的界限，以解决当今神经科学领域的一些最棘手的挑战。

About Genentech Access Solutions

关于Genentech访问解决方案

Access Solutions is part of Genentech’s commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine.

Access Solutions 是 Genentech 致力于帮助人们获取其处方中的 Genentech 药品的承诺的一部分，无论他们的支付能力如何。Access Solutions 的内部专家团队专注于帮助人们应对药品获取和报销流程，并为美国符合条件的无保险或无法承担药品自付费用的患者提供援助。

To date, the team has helped more than 2 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/(866) 422-2377 or visit .

迄今为止，该团队已经帮助超过200万名患者获得了他们所需的药物。请联系Access Solutions (866) 4ACCESS/(866) 422-2377 或访问。

http://www.Genentech-Access.com

http://www.Genentech-Access.com

for more information.

欲了解更多信息。

About Genentech

关于基因泰克

Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

成立于近50年前的基因泰克是一家领先的生物技术公司，致力于发现、开发、生产和销售用于治疗患有严重和危及生命的疾病的药物。该公司是罗氏集团的成员，总部位于加利福尼亚州南旧金山。

For additional information about the company, please visit .

有关公司的更多信息，请访问。

http://www.gene.com

http://www.gene.com

.

。

Indications and Important Safety Information

适应症和重要的安全信息

What are Ocrevus and Ocrevus Zunovo?

什么是奥克雷夫斯和奥克雷夫斯祖诺沃？

Ocrevus and Ocrevus Zunovo are prescription medicines used to treat:

Ocrevus和Ocrevus Zunovo是用于治疗以下疾病的处方药：

It is not known if Ocrevus and Ocrevus Zunovo are safe and effective in children.

目前尚不清楚Ocrevus和Ocrevus Zunovo在儿童中是否安全有效。

Who should not receive Ocrevus and Ocrevus Zunovo?

谁不应该接受Ocrevus和Ocrevus Zunovo？

Do not receive Ocrevus or Ocrevus Zunovo if you:

如果您有以下情况，请勿接受奥克雷珠单抗或奥克雷珠祖诺沃：

What is the most important information I should know about Ocrevus and Ocrevus Zunovo?

我应该了解的关于奥克雷夫斯和奥克雷夫斯祖诺沃的最重要的信息是什么？

Ocrevus and Ocrevus Zunovo can cause serious side effects, including:

Ocrevus 和 Ocrevus Zunovo 可能导致严重的副作用，包括：

Tell your healthcare provider or nurse if you get any of these symptoms:

如果出现以下任何症状，请告知您的医疗保健提供者或护士：

Additionally, for Ocrevus Zunovo:

此外，对于Ocrevus Zunovo：

These infusion and injection reactions can happen during or up to 24 hours after administration. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion or injection.

这些输注和注射反应可能在给药期间或给药后长达24小时内发生。如果您在每次输注或注射后出现上述任何症状或体征，请务必立即联系您的医疗保健提供者。

Before receiving Ocrevus or Ocrevus Zunovo, tell your healthcare provider about all of your medical conditions, including if you:

在接受奥克雷珠单抗或奥克雷珠单抗祖诺沃之前，请告知您的医疗保健提供者您的所有健康状况，包括：

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

告诉您的医疗保健提供者您所服用的所有药物，包括处方药和非处方药、维生素以及草本补充剂。

What are the possible side effects of Ocrevus and Ocrevus Zunovo?

Ocrevus 和 Ocrevus Zunovo 有哪些可能的副作用？

Ocrevus and Ocrevus Zunovo may cause serious side effects, including:

Ocrevus 和 Ocrevus Zunovo 可能导致严重的副作用，包括：

The most common side effects of Ocrevus Zunovo include:

Ocrevus Zunovo最常见的副作用包括：

These are not all the possible side effects of Ocrevus and Ocrevus Zunovo.

这些并非 Ocrevus 和 Ocrevus Zunovo 的全部可能副作用。

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

有关副作用的医疗建议，请咨询您的医生。您可以拨打1-800-FDA-1088向FDA报告副作用。您也可以拨打(888) 835-2555向Genentech报告副作用。

For more information, go to

欲了解更多信息，请访问

https://www.Ocrevus.com

https://www.Ocrevus.com

or call 1-844-627-3887.

或拨打 1-844-627-3887。

For additional safety information, please see the full

有关更多安全信息，请参阅完整内容

Prescribing Information

处方信息

and

和

Medication Guide for Ocrevus

Ocrevus药物指南

.

。

For additional safety information, please see the full

有关更多安全信息，请参阅完整内容

Prescribing Information

处方信息

and

和

Medication Guide for Ocrevus Zunovo

Ocrevus Zunovo用药指南

.

。

###

###